MRPL48 and cancer: Survival analysis indicated that the Overall Survival (OS, defined as the period from suffering to death), Disease-Specific Survival (DSS, reflecting the death from cancer itself), and Progress-Free Intervals (PFI, from the date of randomization for initial treatment to the time of disease relapse) of HCC patients with high MRPL48 expression were significantly lower than patients with low MRPL48 expression (p < 0.01) (Fig. 3E–G).